- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03920202
Long - Term Low Anterior Resection Syndrome (LongLARS)
Long - Term Bowel Dysfunction Following Low Anterior Resection
Study Overview
Status
Conditions
Detailed Description
For the last almost 30 years, the gold standard treatment for RC is low anterior resection (LAR) with total mesorectal excision (TME). Unfortunately, up to 80 % of patients undergoing LAR will suffer of bowel dysfunction including faecal urgency, frequent bowel movements, tenesmus or so called Low Anterior Resection Syndrome (LARS). Simply it has been defined as "disordered bowel function after rectal resection, leading to a detriment in quality of life". Same year LARS score was developed. This tool is easy to use and has been internationally and in Lithuania validated. Wexner score is another tool for evaluation of faecal continence.
There are only five studies investigating long-term results after rectal surgery and influence it has on patients' daily life. In one study 47 of 51 patients experienced LARS following ultra-low anterior resection after average 6.5 years. Another study recently reported major LARS in 46% of the patients with the mean median follow-up of 14.6 years. Others showed that 47.5% of patients still experience LARS symptoms at a follow-up period of 13.7 years. Just recently published study assessed bowel function 12 years in patients undergoing rectal resection with or without preventing ileostomy. Authors found that 63 (72%) patients of 87 experienced LARS symptoms with more than a half complaining of major LARS. Moreover, just last year a study published showing that 73% of patients had LARS at first follow up 5 years after the surgery. During the second visit (another 5 years later) same numbers were seen.
The aim of this study was to evaluate late functional results of patients who underwent rectal resection for rectal cancer. This included calculating LARS and Wexner score and identifying possible risk factors of late postoperative bowel disorders.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Vilnius, Lithuania, 08406
- National Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients diagnosed with rectal cancer without metastasis
- signed consent form
- more than 5 years following the surgery
Exclusion Criteria:
- unwilling to participate
- stage IV disease
- change in operative plan - end colostomy formed
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bowel function assessment using Low anterior resection syndrome questionnaire
Time Frame: 5 years
|
Bowel function following low anterior resection surgery for rectal cancer will be assessed using Low anterior resection syndrome score (LARS score - simple 5 question questionnaire).
LARS score is a tool consisting of five items, which are as follows: incontinence due to flatus (score range from 0 to 7), incontinence due to liquid stools (score range from 0 to 3), frequency of bowel movements (score range from 0 to 5), clustering (score range from 0 to 11) and urgency (score range from 0 to 16).
The severity of each item is calculated on a scale ranging from 0 to 42, with a score of 0-20 (no LARS), 21-29 (minor LARS) and 30-42 (major LARS).
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk factors: age
Time Frame: 5 years
|
Risk factors for having worse bowel function following low anterior resection for rectal cancer - age: older patients (>55years) might have worse bowel function
|
5 years
|
Risk factors: type of surgical procedure
Time Frame: 5 years
|
Risk factors for having worse bowel function following low anterior resection for rectal cancer - type of surgery: rectum resection with total mesorectal excision vs partial mesorectal excision will lead to worse functional outcome.
|
5 years
|
Risk factors: preoperative chemoradiotherapy
Time Frame: 5 years
|
Risk factors for having worse bowel function following low anterior resection for rectal cancer - preoperative chemoradiotherapy might lead to worse functional outcome.
|
5 years
|
Collaborators and Investigators
Investigators
- Study Chair: Narimantas Samapavicius, Prof., Klaipėda university
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LongLARS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bowel; Functional Syndrome
-
King's College LondonCompletedIrritable Bowel Syndrome | Functional Diarrhea | Functional Bowel DisorderUnited Kingdom
-
YE YingjiangCompletedBowel; Functional SyndromeChina
-
University of SuffolkRecruitingIrritable Bowel Syndrome | Food Intolerance | Functional Bowel Disorder | Food Intolerance SyndromesUnited Kingdom
-
Stanford UniversityRecruitingHealthy | Functional Gastrointestinal Disorders | IBS - Irritable Bowel Syndrome | Functional BloatingUnited States
-
BayerCompletedA Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world SettingFunctional Dyspepsia | Irritable Bowel Syndrome | Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional DyspepsiaGermany
-
Baylor College of MedicineUniversity of WashingtonRecruitingIrritable Bowel Syndrome | Functional Abdominal Pain | Functional Gastrointestinal Disorders | Functional Abdominal Pain Syndrome | Functional Bowel Disorder | Functional Abdominal Pain DisordersUnited States
-
National Institute of Diabetes and Digestive and...CompletedIrritable Bowel Syndrome | Abdominal Pain | Constipation | Functional Colonic DiseasesUnited States, Canada
-
AbbVieIronwood Pharmaceuticals, Inc.Active, not recruitingIrritable Bowel Syndrome With Constipation | Functional ConstipationUnited States, Belgium, Bulgaria, Canada, Estonia, Israel, Italy, Netherlands, Poland, Puerto Rico, Spain, Ukraine, United Kingdom, Germany
-
AbbVieIronwood Pharmaceuticals, Inc.Enrolling by invitationIrritable Bowel Syndrome With Constipation | Functional ConstipationUnited States, Canada, Israel, Netherlands
-
University of NottinghamUniversity College, London; Queen Mary University of LondonUnknownConstipation - Functional | Irritable Bowel Syndrome Characterized by ConstipationUnited Kingdom